Compare Celsius Holdings, Inc. (CELH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Celsius Holdings, Inc. trades at $30.85 (market cap $7.71B), while Regeneron Pharmaceuticals Inc trades at $660.77 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.9× Celsius Holdings, Inc.'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Celsius Holdings, Inc. pays none. Which is the better fit depends on your goals.
| CELH | REGN | |
|---|---|---|
Market Cap | $7.71B | $68.79B |
Sector | Consumer Staples | Health |
52-Week High | $64.86 | $812.27 |
52-Week Low | $27.75 | $542.52 |
Enterprise Value | $9.58B | $62.74B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Celsius Holdings (CELH) trades at $29.83, down 2.52% on the day, amid bearish technical signals despite strong analyst support. The stock shows robust revenue growth, with 2025 sales reaching $2.52B, though net margins have compressed to 4.29%. Recent quarters consistently beat EPS estimates, but cash flow turned negative due to heavy investing activity. Legal investigations and competitive pressures weigh on sentiment, while a $52.30 consensus price target implies significant upside.
Outlook remains bifurcated: high growth potential and international expansion contrast with margin pressure and litigation risks. Investors face a volatile growth story where execution on profitability and market share gains will dictate performance. The stock's high P/E of 71.16 demands sustained earnings acceleration to justify valuation.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
